Are you Dr. Krueger?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1230 York Ave
New York, NY 10065Phone+1 212-327-8091
Summary
- Dr. James Krueger, MD is a board certified dermatologist in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Dermatology, 1986 - 1990- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1985 - 1986
Weill Cornell MedicineClass of 1985
Certifications & Licensure
NY State Medical License 1986 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1995
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris Start of enrollment: 1997 Oct 01
- To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris Start of enrollment: 1997 Oct 01
- Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis Start of enrollment: 2003 Aug 04
- Join now to see all
Publications & Presentations
PubMed
- Skin immune-mesenchymal interplay within tertiarylymphoid structures promotes autoimmunepathogenesis in hidradenitis suppurativa.Wei-Wen Yu, Joy N P Barrett, Jie Tong, Meng-Ju Lin, Meaghan Marohn
Immunity. 2024-12-10 - Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood.Tali Czarnowicki, Eden David, Kazuhiko Yamamura, Joseph Han, Helen He
Allergy. 2024-10-01 - Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasi...Ian M Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, James G Krueger
Dermatology and Therapy. 2024-10-01
Press Mentions
Recharacterization of Hidradenitis Suppurativa Pathology UnderwayDecember 17th, 2024- Hidradenitis Suppurativa: Nodules Respond to as Needed Topical JAK InhibitorOctober 18th, 2024
- Topical JAK Inhibitor Controls Hidradenitis Suppurativa Nodules for 32 WeeksOctober 3rd, 2024
- Join now to see all
Professional Memberships
- Fellow
